Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Kidney and Urinary TractDRG 694-urinary-stones-without-mcc
    Ask Trek AI about this page

    Urinary Stones without MCC: Inpatient Reimbursement Overview

    DRG 694 encompasses inpatient encounters for urinary stones without a Major Complication or Comorbidity, focusing on cases managed surgically or conservatively with lower resource needs. It matters for inpatient reimbursement because grouping into this Diagnosis-Related Group influences Medicare payment amounts and hospital case-mix reporting.

    Customize your policy alerts

    Sign up for drg 694 policy alerts

    Get alerted when payer policies referencing 694 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 694 Overview

    DRG 694 covers inpatient admissions for urinary stone disease without a Major Complication or Comorbidity and typically includes diagnoses such as renal or ureteral calculi managed with procedures like ureteroscopy, lithotripsy, or stent placement. This Diagnosis-Related Group groups patients with relatively low resource intensity compared with cases that have complications, which affects payment assignment and length-of-stay expectations under Medicare inpatient prospective payment policies. Accurate coding of diagnoses and related procedures determines classification into this Diagnosis-Related Group and therefore impacts Medicare reimbursement. Clinical documentation that distinguishes absence of Major Complication or Comorbidity is essential for correct grouping.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Acute procedural efficacy and safety studies: Trials comparing minimally invasive interventions such as ureteroscopy, shock wave lithotripsy, and percutaneous nephrolithotomy for immediate stone clearance in hospitalized patients with obstructing ureteral or renal calculi. These studies enroll adult inpatients presenting with symptomatic stones (pain, infection risk, or obstruction) and focus on short-term outcomes like stone-free rates, complication rates, procedure time, need for repeat intervention, and length of stay. Results are directly relevant to surgeons, hospitalists, and payers because they inform choice of index procedure that can reduce complications, resource utilization, and inpatient costs.
    • Comparative effectiveness and care pathway trials for conservatively managed stones: Randomized or pragmatic studies that compare active surveillance with medical expulsive therapy, optimized pain control protocols, or early outpatient versus inpatient management for patients with small non-obstructing ureteral stones. These trials typically enroll patients admitted or observed for stone-related pain but who may not require immediate surgery, assessing outcomes such as spontaneous passage rates, subsequent admissions or procedures, analgesic use, and patient-reported pain and function. Findings guide clinicians and payers on which nonoperative pathways safely reduce inpatient interventions and readmissions while maintaining patient-centered outcomes and overall cost-effectiveness.
    • Post-discharge prevention and recurrence reduction studies: Longitudinal interventional or cohort studies testing metabolic evaluation pathways, dietary and pharmacologic prevention strategies, or care-coordination programs aimed at reducing recurrent stone events and future admissions among patients recently hospitalized for urinary stones. These studies focus on patients discharged after an acute stone episode and measure adherence to prevention plans, recurrence rates, healthcare utilization (ED visits, readmissions), and cost offsets over months to years. For providers and payers, evidence from these studies supports investment in outpatient prevention services that can lower recurrent admissions, downstream procedures, and long-term expenditures associated with this DRG.

    Related Codes

    650-KIDNEY-TRANSPLANT-WITH-HEMODIALYSIS-WITH-MCC

    Kidney Transplant with Hemodialysis with Major Complication or Comorbidity: Inpatient Reimbursement Overview

    651-KIDNEY-TRANSPLANT-WITH-HEMODIALYSIS-WITHOUT-MCC

    Kidney Transplant with Hemodialysis without MCC: Inpatient Reimbursement Overview

    652-KIDNEY-TRANSPLANT

    Kidney Transplant: Inpatient Reimbursement Overview

    653-MAJOR-BLADDER-PROCEDURES-WITH-MCC

    Major Bladder Procedures with MCC: Inpatient Reimbursement Overview

    654-MAJOR-BLADDER-PROCEDURES-WITH-CC

    Major Bladder Procedures with CC: Inpatient Reimbursement Overview

    655-MAJOR-BLADDER-PROCEDURES-WITHOUT-CC-MCC

    Major Bladder Procedures without CC/MCC: Inpatient Reimbursement Overview

    656-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITH-MCC

    Kidney and Ureter Procedures for Neoplasm with MCC: Inpatient Reimbursement Overview

    657-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITH-CC

    Kidney and Ureter Procedures for Neoplasm with CC: Inpatient Reimbursement Overview

    658-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITHOUT-CC-MCC

    Kidney and Ureter Procedures for Neoplasm without CC/MCC: Inpatient Reimbursement Overview

    659-KIDNEY-AND-URETER-PROCEDURES-FOR-NON-NEOPLASM-WITH-MCC

    Kidney and Ureter Procedures for Non-Neoplasm with MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 41

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.